Last reviewed · How we verify

NCT06315777

GREM1, HAS2 and PTGS2 Gene Expression Following the in Vitro Maturation (IVM)

Status unknown NA Last updated 18 March 2024
What this trial tests

NA trial testing cumulus cell oocytes complex (COC) among women with poor ovarian reserve in Increased Oocyte Death in 30 participants. Status unknown.

Timeline
1 July 2021
Primary endpoint
1 July 2024
31 July 2024

Quick facts

Lead sponsorNational University of Malaysia
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment30
Start date1 July 2021
Primary completion1 July 2024
Estimated completion31 July 2024
Sites1 location across Malaysia

Drugs / interventions tested

Conditions studied

Sponsor

National University of Malaysia

Who can join

Adults 18 to 45, female only, with Increased Oocyte Death or in Vitro Maturation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Poor ovarian reserve (POR) is an adverse prognostic factor for In-Vitro Fertilization (IVF) success. Numerous established data showed low live birth rates per IVF cycle; 6 to 10%, including the usage of In-Vitro Maturation (IVM). In Malaysia, POR incidence increases mainly from cancer survival, endometriosis, and autoimmune diseases women; therefore, IVM implementation is paramount. In the molecular level, the low competence oocytes showed a low expression of GREM1, HAS2 and PTGS2 in human cumulus cells, thus leading to poor oocyte quality(OQ). Various IVM media had been formulated to enhance the competency and quality of the oocytes to date. Therefore, our study aims to elucidate the GREM1, HAS2 and PTGS2 gene expression as oocyte developmental competency markers among POR women following IVM and tailored to the IVF outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other National University of Malaysia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06315777.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing